Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
Bio-Path Holdings (NASDAQ:BPTH) announced that CEO Peter Nielsen will give a pre-recorded presentation at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 7:00 a.m. ET. The presentation will be available via audio webcast on the company's website for approximately 90 days.
Bio-Path is developing DNAbilize®, a novel RNAi nanoparticle drug delivery technology. Their pipeline includes:
- Prexigebersen (BP1001): In Phase 2 for blood cancers
- BP1001-A: In Phase 1/1b for solid tumors
- BP1002: Targeting Bcl-2 protein for blood cancers and solid tumors
- BP1003: STAT3 inhibitor with upcoming IND application
The company's technology allows for simple intravenous infusion of their targeted nucleic acid cancer drugs.
Bio-Path Holdings (NASDAQ:BPTH) ha annunciato che il CEO Peter Nielsen presenterà una relazione pre-registrata alla 26ª Conferenza Annuale di Investimenti Globali H.C. Wainwright il 9 settembre 2024, alle 7:00 a.m. ET. La presentazione sarà disponibile tramite webcast audio sul sito web dell'azienda per circa 90 giorni.
Bio-Path sta sviluppando DNAbilize®, una nuova tecnologia di somministrazione di farmaci a nanoparticelle RNAi. Il loro pipeline include:
- Prexigebersen (BP1001): In Fase 2 per i tumori del sangue
- BP1001-A: In Fase 1/1b per tumori solidi
- BP1002: Mira alla proteina Bcl-2 per tumori del sangue e solidi
- BP1003: Inibitore di STAT3 con prossima applicazione IND
La tecnologia dell'azienda consente una semplice infusione endovenosa dei loro farmaci oncologici a base di acidi nucleici mirati.
Bio-Path Holdings (NASDAQ:BPTH) anunció que el CEO Peter Nielsen hará una presentación pregrabada en la 26ª Conferencia Anual de Inversiones Globales H.C. Wainwright el 9 de septiembre de 2024, a las 7:00 a.m. ET. La presentación estará disponible a través de una transmisión de audio en el sitio web de la empresa durante aproximadamente 90 días.
Bio-Path está desarrollando DNAbilize®, una novedosa tecnología de entrega de fármacos mediante nanopartículas RNAi. Su pipeline incluye:
- Prexigebersen (BP1001): En Fase 2 para cánceres de sangre
- BP1001-A: En Fase 1/1b para tumores sólidos
- BP1002: Dirigido a la proteína Bcl-2 para cánceres de sangre y tumores sólidos
- BP1003: Inhibidor de STAT3 con próxima solicitud IND
La tecnología de la empresa permite una simple infusión intravenosa de sus fármacos oncológicos de ácido nucleico dirigidos.
Bio-Path Holdings (NASDAQ:BPTH)는 CEO인 Peter Nielsen이 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에서 2024년 9월 9일 오전 7시(ET)에 사전 녹화된 발표를 할 것이라고 발표했습니다. 이 발표는 회사 웹사이트를 통해 약 90일 동안 오디오 웹캐스트로 제공될 예정입니다.
Bio-Path는 DNAbilize®라는 새로운 RNAi 나노입자 약물 전달 기술을 개발하고 있습니다. 그들의 파이프라인에는 다음과 같은 제품이 포함되어 있습니다:
- Prexigebersen (BP1001): 혈액암에 대한 2상 진행 중
- BP1001-A: 고형 종양에 대한 1/1b상 진행 중
- BP1002: 혈액암 및 고형 종양을 겨냥한 Bcl-2 단백질
- BP1003: 곧 IND 신청이 예정된 STAT3 억제제
회사의 기술은 타겟 핵산 암약물의 간단한 정맥 주입을 가능하게 합니다.
Bio-Path Holdings (NASDAQ:BPTH) a annoncé que le PDG Peter Nielsen donnera une présentation pré-enregistrée lors de la 26e Conférence Annuelle d'Investissement Global H.C. Wainwright le 9 septembre 2024 à 7h00 ET. La présentation sera disponible via un webcast audio sur le site de l'entreprise pendant environ 90 jours.
Bio-Path développe DNAbilize®, une nouvelle technologie de livraison de médicaments par nanoparticules RNAi. Leur pipeline comprend :
- Prexigebersen (BP1001): En phase 2 pour les cancers du sang
- BP1001-A: En phase 1/1b pour les tumeurs solides
- BP1002: Vise la protéine Bcl-2 pour les cancers du sang et les tumeurs solides
- BP1003: Inhibiteur de STAT3 avec une demande IND à venir
La technologie de l'entreprise permet une simple infusion intraveineuse de leurs médicaments anticancéreux à base d'acides nucléiques ciblés.
Bio-Path Holdings (NASDAQ:BPTH) gab bekannt, dass CEO Peter Nielsen am 9. September 2024 um 7:00 Uhr ET eine vorab aufgezeichnete Präsentation auf der 26. Jahreskonferenz für globale Investitionen von H.C. Wainwright halten wird. Die Präsentation wird für etwa 90 Tage über ein Audio-Webcast auf der Unternehmenswebsite verfügbar sein.
Bio-Path entwickelt DNAbilize®, eine neuartige RNAi-Nanopartikel-Arzneimittelabgabetechnologie. Ihr Pipeline umfasst:
- Prexigebersen (BP1001): In Phase 2 für Blutkrebse
- BP1001-A: In Phase 1/1b für solide Tumoren
- BP1002: Zielt auf Bcl-2-Protein für Blutkrebse und solide Tumoren
- BP1003: STAT3-Inhibitor mit bevorstehender IND-Anwendung
Die Technologie des Unternehmens ermöglicht eine einfache intravenöse Infusion ihrer zielgerichteten nucleinsäurebasierten Krebsmedikamente.
- None.
- None.
HOUSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright 26th Annual Global Investment Conference made available on Monday, September 9, 2024 at 7:00 a.m. ET.
An audio webcast of the presentation will be available here and on the Investor Relations section of Bio-Path’s website, where it will be archived for approximately 90 days.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND application is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These statements are based on management's current expectations and accordingly are subject to uncertainty and changes in circumstances. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path’s ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies, the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, the maintenance of intellectual property rights, that patents relating to existing or future patent applications will be issued or that any issued patents will provide meaningful protection of our drug candidates, the impact, risks and uncertainties related to global pandemics, including the COVID-19 pandemic, and actions taken by governmental authorities or others in connection therewith, and such other risks which are identified in Bio-Path's most recent Annual Report on Form 10-K, in any subsequent quarterly reports on Form 10-Q and in other reports that Bio-Path files with the Securities and Exchange Commission from time to time. These documents are available on request from Bio-Path Holdings or at www.sec.gov. Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
FAQ
When is Bio-Path Holdings (BPTH) presenting at the H.C. Wainwright Global Investment Conference?
What is Bio-Path Holdings' (BPTH) main technology platform?
Which product candidates are in Bio-Path Holdings' (BPTH) pipeline?
How are Bio-Path Holdings' (BPTH) drug candidates administered?
What is the target of Bio-Path Holdings' (BPTH) lead product candidate, prexigebersen?
